European Pharma Buyers Are Looking More Closely at What Development Services Actually Cover
Choosing an external development service can seem fairly simple until a pharmaceutical team starts going through the details. A provider may offer support for clinical-stage work, but the buyer still has to work out exactly what that means for the program. For European pharmaceutical and therapeutic developers, the line between external support and internal responsibility can affect how smoothly the arrangement works.
The question often comes up during procurement. A company may know it needs additional help without having decided which parts of the development work should remain with its own team. That can depend on the resources already available internally and where the drug candidate is in its development.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Requirements can also change as the program moves forward. A service that fits the work at one point may not cover what the team needs later. Buyers, therefore, have a reason to look beyond the immediate assignment and consider whether the arrangement can adjust if the development program takes a different direction.
That does not mean a broader service is automatically the better choice. A wider scope can include work that the company already handles internally. A more limited arrangement may make more sense when the developer has the people and processes to manage certain responsibilities itself. The starting point is knowing what the company actually needs.
This makes early conversations with a provider particularly useful. Buyers need a clear understanding of what the external team will handle and what stays inside the pharmaceutical company. If those boundaries are left vague, questions can surface later about tasks that neither side expected the other to take responsibility for.
Communication creates another practical consideration. Clinical development involves information moving between people who may work for different organizations. Once an outside provider becomes involved, the pharmaceutical company needs a workable way to keep the relevant information moving between internal staff and the external team.
For European buyers, the provider’s location may be part of the decision, but it does not necessarily settle the question. The more immediate issue is whether the provider can fit into the company’s development process. Responsibilities need to be clear enough that everyone involved understands who is handling a particular part of the work.
Cost deserves a similar level of attention. The quoted price for an external service does not always reflect the amount of internal time needed to manage the relationship. Employees may have to coordinate activities or resolve questions about responsibility. That additional effort can change how the arrangement looks once the work is underway.
This is not an argument against external development support. A provider can give a pharmaceutical company access to expertise or capacity that it does not want to maintain entirely in-house. The procurement question is more practical: whether the arrangement reduces a specific workload without creating another layer of administration around it.
Providers may find that buyers are asking more detailed questions before an engagement begins. Instead of focusing only on what a service includes, procurement discussions may examine how responsibilities are divided and what happens when the development program changes.
For pharmaceutical companies, this creates a more useful way to compare clinical-stage development services. The longest service description is not necessarily the best fit. What matters is whether the proposed arrangement matches the work the company actually needs handled and leaves fewer unanswered questions about responsibility.
European clinical-stage pharmaceutical and therapeutic development solutions can take different forms depending on the developer and their program. Buyers do not need every provider to follow the same model. They do need enough clarity to understand what they are purchasing, what remains in-house and how the working relationship will function once the clinical development work begins.
More in News
The life sciences industry, encompassing pharmaceuticals, biotechnology, medical devices, and related fields, is an ever-evolving sector at the forefront of human health and well-being. Integral to its continuous advancement is a robust and adaptive ecosystem of training services. These services are crucial for equipping professionals with the specialised knowledge and skills required to navigate complex scientific, technological, and regulatory landscapes.
Evolving Modalities and Diverse Curricula
At its core, life science training aims to foster a highly skilled workforce, from entry-level technicians to seasoned researchers and executives. This encompasses a broad spectrum of educational offerings, ranging from foundational scientific principles to advanced technical proficiencies and intricate regulatory compliance. Traditional classroom-based instruction remains relevant, particularly for in-depth theoretical understanding and the delivery of structured curricula. However, the industry has seen a significant proliferation and diversification of training modalities, driven by technological advancements and the need for greater accessibility and flexibility. The adaptability of professionals in embracing new training modalities is a testament to their commitment to staying current in the rapidly changing industry.
E-learning platforms have emerged as a cornerstone of modern life science training. These platforms offer a wealth of on-demand courses, interactive modules, and virtual simulations, allowing professionals to learn at their own pace and from any location. This flexibility has become even more valuable in the wake of the COVID-19 pandemic, which has accelerated the adoption of remote learning in a globalised industry where continuous professional development is paramount. Live online sessions, often blending expert instruction with interactive elements, also provide a dynamic learning experience, fostering real-time engagement and discussion. Many training providers now offer a hybrid approach, combining the benefits of virtual learning with periodic in-person workshops to provide hands-on experience and facilitate networking.
The content of life science training is incredibly diverse, reflecting the multifaceted nature of the industry. Core scientific disciplines such as molecular biology, biochemistry, pharmacology, and genetics form the bedrock of many programs. Beyond these fundamentals, specialised training areas are critical. For instance, in drug discovery and development, training encompasses everything from target identification and lead optimisation to clinical trial design, data management, and pharmacovigilance. Manufacturing and quality assurance are other significant domains, with courses covering Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Quality Management Systems (QMS) to ensure product safety and efficacy.
Specialised Knowledge and Complementary Skills
Regulatory affairs training is of paramount importance in the life sciences. Given the stringent regulations governing product development, approval, and marketing across different global jurisdictions, professionals require deep expertise in areas such as the FDA, EMA, and other regional guidelines. This includes training on regulatory submissions, post-market surveillance, and adherence to evolving compliance standards. The role of regulatory bodies in shaping the training landscape cannot be overstated, as they drive the need for continuous learning and adaptation to new standards and regulations. The rise of new modalities, such as cell and gene therapies and advanced therapy medicinal products (ATMPs), has further necessitated specialized training in their unique regulatory pathways and manufacturing considerations.
Beyond scientific and regulatory knowledge, the modern life science professional requires a blend of complementary skills. Training programs increasingly incorporate modules on data analytics, bioinformatics, and the application of artificial intelligence and machine learning in research, development, and clinical settings. The ability to interpret complex datasets, utilize computational tools for drug discovery, and leverage AI for predictive modeling is becoming essential. However, it's necessary to note that soft skills, such as effective scientific communication, technical writing, project management, and leadership, are equally vital for success in collaborative and interdisciplinary environments. The industry is recognizing the importance of these skills, and training in these areas helps professionals not only excel in their technical roles but also to articulate scientific findings, lead teams, and navigate the commercial aspects of the industry.
Practical Application and Future Directions
A notable trend in the life science training landscape is the increasing emphasis on practical, skill-based learning. This goes beyond theoretical knowledge to focus on the application of concepts in real-world scenarios. Many programs now offer hands-on laboratory training, virtual lab simulations, and opportunities to work on industry-relevant projects. This practical orientation ensures that graduates and professionals are not only knowledgeable but also proficient in executing tasks and solving problems encountered in their daily work. The value of these practical skills in the industry cannot be overstated, as they provide professionals with the confidence to apply their knowledge effectively.
The future trajectory of life science training services is closely intertwined with the ongoing evolution of the broader industry. The accelerating pace of scientific discovery, the increasing complexity of therapeutic modalities, and the pervasive integration of digital technologies are all shaping the demand for specific skill sets. Training providers are continuously adapting their curricula to address emerging areas such as personalized medicine, digital health technologies (e.g., wearables, telemedicine), and advanced manufacturing techniques like 3D printing for medical devices. The focus will likely intensify on interdisciplinary training, bridging the gap between traditional life sciences and advanced computing, engineering, and data science. As the industry moves towards more integrated and patient-centric approaches, training will also emphasize understanding the entire product lifecycle and the broader healthcare ecosystem. ...Read more
Healthcare is moving from reactive treatment to proactive care. Clinicians are looking for better ways to anticipate disease progression and facilitate timely and appropriate interventions. AI-based prognostic testing is playing an important role in this transformation to estimate the probability of future health outcomes by analyzing complex clinical information. These technologies are not intended to replace medical expertise. They would rather provide decision support tools that help healthcare professionals to process massive amounts of data more efficiently and to detect patterns that may not be obvious.
AI-based prognostic solutions are being integrated into clinical workflows for risk assessment, treatment planning, patient monitoring and long-term management of care. With increased computing power and medical data, these systems are becoming more accurate, efficient and clinically relevant. Healthcare providers need more transparency about how AI systems make predictions so they can confidently interpret recommendations. Better interpretability of models supports responsible clinical use and promotes more trust in AI-assisted decision support.
How Are AI-Based Prognostic Testing Solutions Advancing?
Current AI systems are capable of analyzing data from sources including medical images, laboratory results, clinical records, genomic data, and physiological measurements. Bringing these datasets together gives a fuller view of a patient’s state, allowing for better clinical judgment. In clinical data, advanced algorithms may detect subtle relationships that can help healthcare professionals make predictions regarding disease progression, recovery patterns or likelihood of complications. These insights support earlier intervention and more personalized treatment strategies, but within the framework of the overall clinical decision-making process.
AI systems are evolving beyond population-based models by incorporating individual patient characteristics, medical history and clinical information in real time. Therna Biosciences combines proprietary experimental data and machine learning to support the design of programmable RNA medicines. This enables clinicians to customize care plans that better fit each patient’s individual situation. As healthcare increasingly embraces precision medicine and digital transformation, AI-based prognostic testing is becoming increasingly relevant to delivering proactive, personalized and data-driven care.
What Technologies Are Shaping the Future of Prognostic Testing?
Analytics are being increasingly integrated with AI to support clinical decision-making. Models can be updated as new clinical evidence, research results and validated healthcare data become available, helping to keep systems relevant and support changes in medical practice. Cloud-based clinical platforms are enhancing collaboration by providing authorized healthcare teams with secure access to prognostic data, patient records and analytical tools across different care settings.
Etiometry uses continuous physiologic data and clinical intelligence to help clinicians interpret patient risk in real time.
Automation is increasing the efficiency of data processing by minimizing the need for manual administrative work to gather, organize and evaluate clinical information. AI-powered prognostic testing is emerging as a useful addition in the modern healthcare setting to help enable earlier risk identification, customized treatment planning, and more streamlined clinical workflows. Organizations that combine advanced AI capabilities with strong clinical validation, transparency and governance will be best placed to improve patient outcomes and form the foundation of predictive healthcare of the future. ...Read more
Proficiency testing is less useful when the challenge is easy to predict. A laboratory can do well with familiar concentrations and still have weaknesses in how it chooses a method or interprets results. For life science leaders, the bigger question is whether a program can bring those weaknesses to light before they affect routine reporting. Accreditation is important, but it does not tell buyers how well the test itself has been designed. What matters is whether the scheme simply confirms that a laboratory can perform routine testing or also shows where its test system may start to struggle. Buyers therefore need enough detail on sample construction and scoring to know what a satisfactory result really says about laboratory performance.
A proficiency score can look reassuring when the specimens are too simple, but it does not necessarily show how a method will perform when conditions are less predictable. A useful program should reveal how the method responds when organisms compete, analyte levels shift, matrix chemistry interferes or non-type strains make results harder to interpret. The exercise should put routine methods through a realistic test without making the conditions feel artificial. Concentration ranges should help identify where interpretation becomes difficult, while matrix choices should reflect the chemistry and microbial background laboratories actually encounter. Ready-to-test materials can reduce preparation differences too, making it easier to tell whether a poor result comes from the test system or the exercise itself. The challenge should test judgment as well.
A clean result from one analyst does not tell you much about variation across the rest of the laboratory. Broader participation allows laboratories to compare performance across staff or repeated result sets without making the exercise an unreasonable budget burden. Poor scores should also lead to something useful. Reporting alone has limited value if laboratories cannot investigate an outlier and use the finding to revise a procedure. Technical dialogue becomes valuable at that stage, provided the provider helps clarify the result without taking over the laboratory’s own root-cause work. Repeated participation should then show whether corrective changes are holding rather than simply closing out a single incident.
“IFM Quality Services permits multiple result submissions without extra fees, allowing broader laboratory participation in the same exercise.”
Finding the right program is not always straightforward when laboratories use different microbiological methods and sample matrices. A generic exercise may not pick up problems that are specific to a particular method, especially when molecular techniques or unusual materials affect how results are interpreted. That is why buyers should check whether a program actually covers the test methods and sample types used in their laboratory, rather than relying on a standard template. The materials themselves deserve attention too. Base material, presentation format, shelf life and storage conditions can all influence the usefulness of the results. Consistent production and documented quality control should be part of the buying decision, not something left to the back office. Programs should also be reviewed over time, with sample formats changing when recurring results point to limitations in the exercise.
For laboratories that expect proficiency testing to do more than confirm routine performance, IFM Quality Services is a provider worth considering. Its microbiological programs include multiple samples and different analyte levels, with real ready-to-test materials used where practical. Laboratories can also submit results multiple times without paying extra fees, making it easier for more staff to take part in the same exercise. The programs cover foods, pharmaceuticals, water and generic sample types, including samples developed for PCR-based methods. IFM produces reference materials as well as proficiency testing programs. It also runs an accredited biological testing laboratory, keeping its program design closely connected to laboratory practice. Where sample challenge and method relevance matter, IFM provides a practical option beyond straightforward pass-fail confirmation. ...Read more
Healthcare organizations are increasingly focusing on improving coordination, accessibility and service efficiency to create a more connected experience for patients and providers. Integrated pharmacy network services are helping strengthen communication between pharmacies, healthcare stakeholders and patients through better-connected systems and streamlined operations. These services support smoother information exchange, improved medication management and more consistent access to pharmacy resources, enabling healthcare networks to respond more effectively to patient needs while creating a more organized approach to care delivery.
Current Market Trends Shaping Integrated Pharmacy Network Services
Digital transformation is becoming a significant influence on the development of integrated pharmacy network services. Pharmacy networks are increasingly adopting advanced platforms that improve operational visibility, support datadriven decision-making and enhance interactions between different points of service. These digital capabilities are helping organizations manage pharmacy activities more effectively while creating smoother workflows across healthcare networks.
The shift towards personalized healthcare is also affecting the way pharmacy networks offer services to various patient groups. Organizations are increasingly looking at solutions that consider individual needs for healthcare, the treatment pathways and patient preferences. As a result, pharmacy networks are being incentivized to create more responsive service models that enhance the customer experience for those relying on pharmacy support.
The use of automation and advanced pharmacy technologies is gaining attention as organizations look for ways to improve accuracy and efficiency in daily operations. Automated processes, digital tools and technology-enabled solutions are helping pharmacy networks reduce manual workloads and optimize routine activities. This trend is encouraging the adoption of modern practices that support more reliable and scalable pharmacy services.
Key Challenges and Solutions in Integrated Pharmacy Network Services
Regulatory disparities within healthcare jurisdictions continue to be a critical challenge that poses difficulties for the provision of integrated pharmaceutical services. This is especially evident when there are disparities within healthcare regulations, compliance requirements and standard operating procedures. Strengthening regulatory monitoring, establishing clear compliance processes and working closely with local experts can help networks navigate these complexities more effectively.
Pharmacy networks also deal with sensitive healthcare data, so preserving strong data security is another big concern. Ensuring that patient records are secure and cannot be accessed or viewed by unauthorized individuals requires a high degree of security, but also constant monitoring. To combat these risks, organizations are investing in enhanced cybersecurity measures that include controlled access systems as well as ongoing auditing of information protection protocols.
“Digital transformation is becoming a significant influence on the development of integrated pharmacy network services.”
As networks expand into new areas, it can be difficult to keep practices consistent between the multiple pharmacy locations. This variance in operating procedures, service protocols and the availability of resources can result in reduced uniformity throughout the network. To combat this, organizations are adopting standard operating procedures, forming common service frameworks and driving regular quality reviews to achieve better consistency across locations.
Managing costs associated with network expansion and service improvement can also create pressure for pharmacy organizations. Investments in infrastructure, workforce requirements and operational upgrades may require careful financial planning. Organizations are responding by evaluating resource allocation, improving process efficiency and adopting strategies that support better cost management.
A continuing key challenge for integrated pharmacy network services is developing a competent workforce capable of managing complex pharmacy operations. Differences in technical knowledge, operational experience and role-specific expertise can influence service effectiveness. Organizations are responding through professional training programs, skill enhancement initiatives and knowledge-sharing practices that help employees perform their responsibilities more effectively.
Diligent quality control can also become difficult when organizations must juggle multiple service points and operational processes as part of integrated pharmacy networks. Inconsistencies in performance standards or divergences in internal practices can impair overall reliability. To address this challenge, organizations have developed quality assurance frameworks, performance monitoring systems and regularly operational evaluations to ensure consistent service delivery.
Future Prospects and Innovations
Future opportunities for integrated pharmacy network services are expected to expand as healthcare systems continue to adopt more connected and outcome-focused service models. Organizations are likely to explore broader pharmacy networks that support stronger integration with wider healthcare delivery systems while responding to changing industry expectations. This direction is expected to create new opportunities for service providers to strengthen their market presence and broaden the scope of pharmacy network services.
The future innovation is expected to focus on creating more intelligent pharmacy network ecosystems that strengthen planning, coordination and long-term operational agility. Organizations are likely to place greater emphasis on predictive service planning, adaptive resource management and more responsive network strategies to address changing healthcare demands. These developments are expected to encourage more proactive decision-making and support increasingly flexible pharmacy network operations.
The long-term outlook for integrated pharmacy network services remains encouraging as the industry continues to evolve alongside broader healthcare transformation. Continued progress is expected to strengthen the strategic role of pharmacy networks within healthcare delivery while encouraging greater collaboration, wider industry participation and ongoing innovation. This direction is likely to reinforce the importance of integrated pharmacy network services in supporting the future development of healthcare systems. ...Read more
